Lantheus Holdings, Inc. $LNTH Stock Position Decreased by Legal & General Group Plc

Legal & General Group Plc cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 22.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,496 shares of the medical equipment provider’s stock after selling 31,821 shares during the quarter. Legal & General Group Plc’s holdings in Lantheus were worth $7,354,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Hantz Financial Services Inc. boosted its stake in shares of Lantheus by 263.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,788 shares of the medical equipment provider’s stock worth $119,000 after acquiring an additional 1,296 shares in the last quarter. Covestor Ltd boosted its position in shares of Lantheus by 49.5% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 862 shares during the period. Larson Financial Group LLC boosted its position in shares of Lantheus by 324.5% in the fourth quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 503 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Lantheus by 12.5% in the fourth quarter. Handelsbanken Fonder AB now owns 20,700 shares of the medical equipment provider’s stock worth $1,378,000 after buying an additional 2,300 shares during the period. Finally, Resona Asset Management Co. Ltd. boosted its position in shares of Lantheus by 35.7% in the fourth quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 292 shares during the period. 99.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Truist Financial reaffirmed a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Price Performance

LNTH opened at $100.98 on Friday. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of 24.33 and a beta of -0.03. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $104.00. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The stock has a fifty day moving average price of $88.01 and a 200 day moving average price of $74.96.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts forecast that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.